Literature DB >> 24900446

Virtual Screening and X-ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group.

Guyan Liang1, Xin Chen1, Suzanne Aldous1, Su-Fen Pu1, Shujaath Mehdi1, Elaine Powers1, Andrew Giovanni1, Sathapana Kongsamut1, Tianhui Xia1, Ying Zhang1, Rachel Wang1, Zhongli Gao1, Gregory Merriman1, Larry R McLean1, Isabelle Morize1.   

Abstract

A series of compounds with an amidinothiophene P1 group and a pyrrolidinone-sulphonamide scaffold linker was identified as potent inhibitors of human kallikrein 6 by structure-based virtual screening based on the union accessible binding space of serine proteases. As the first series of potent nonmechanism-based hK6 inhibitors, they may be used as tool compounds for target validation. An X-ray structure of a representative compound complexed with hK6, resolved at a resolution of 1.88 Å, revealed that the amidinothiophene moiety bound in the S1 pocket and the pyrrolidinone-sulphonamide linker projected the aromatic tail into the S' pocket.

Entities:  

Keywords:  X-ray crystallography; human kallikrein 6; inhibitor; molecular modeling; multiple sclerosis; serine protease; virtual screening

Year:  2012        PMID: 24900446      PMCID: PMC4025863          DOI: 10.1021/ml200291e

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  30 in total

1.  Design, synthesis, and biological activity of potent and selective inhibitors of mast cell tryptase.

Authors:  Corey R Hopkins; Mark Czekaj; Steven S Kaye; Zhongli Gao; James Pribish; Henry Pauls; Guyan Liang; Keith Sides; Dona Cramer; Jennifer Cairns; Yongyi Luo; Heng-Keang Lim; Roy Vaz; Sam Rebello; Sebastian Maignan; Alain Dupuy; Magali Mathieu; Julian Levell
Journal:  Bioorg Med Chem Lett       Date:  2005-06-02       Impact factor: 2.823

2.  A comprehensive nomenclature for serine proteases with homology to tissue kallikreins.

Authors:  Ake Lundwall; Vimla Band; Michael Blaber; Judith A Clements; Yves Courty; Eleftherios P Diamandis; Hans Fritz; Hans Lilja; Johan Malm; Lois J Maltais; A Yvonne Olsson; Constantina Petraki; Andreas Scorilas; Georgia Sotiropoulou; Ulf-Håkan Stenman; Carsten Stephan; Maroulio Talieri; George M Yousef
Journal:  Biol Chem       Date:  2006-06       Impact factor: 3.915

3.  Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system.

Authors:  Matthew J Bernett; Sachiko I Blaber; Isobel A Scarisbrick; Pushparani Dhanarajan; Steven M Thompson; Michael Blaber
Journal:  J Biol Chem       Date:  2002-04-30       Impact factor: 5.157

Review 4.  Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.

Authors:  Aaron M LeBeau; Maya Kostova; Charles S Craik; Samuel R Denmeade
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

5.  A conformationally constrained inhibitor with an enhanced potency for β-tryptase and stability against semicarbazide-sensitive amine oxidase (SSAO).

Authors:  Guyan Liang; Yong Mi Choi-Sledeski; Gregory Poli; Xin Chen; Patrick Shum; Anne Minnich; Qingping Wang; Joseph Tsay; Keith Sides; Jennifer Cairns; Gregory Stoklosa; Thaddeus Nieduzak; Zhicheng Zhao; Jie Wang; Roy J Vaz
Journal:  Bioorg Med Chem Lett       Date:  2010-09-06       Impact factor: 2.823

Review 6.  Kallikrein-related peptidases.

Authors:  A Lundwall; M Brattsand
Journal:  Cell Mol Life Sci       Date:  2008-07       Impact factor: 9.261

7.  Novel small molecule inhibitors for prostate-specific antigen.

Authors:  Hannu Koistinen; Gerd Wohlfahrt; Johanna M Mattsson; Ping Wu; Juhani Lahdenperä; Ulf-Håkan Stenman
Journal:  Prostate       Date:  2008-08-01       Impact factor: 4.104

8.  Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma.

Authors:  Liu-Ying Luo; Shannon J C Shan; Marc B Elliott; Antoninus Soosaipillai; Eleftherios P Diamandis
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

Review 9.  Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.

Authors:  Georgios Pampalakis; Georgia Sotiropoulou
Journal:  Biochim Biophys Acta       Date:  2007-06-14

10.  Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer.

Authors:  Aaron M LeBeau; Sangeeta R Banerjee; Martin G Pomper; Ronnie C Mease; Samuel R Denmeade
Journal:  Bioorg Med Chem       Date:  2009-06-13       Impact factor: 3.641

View more
  3 in total

1.  Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7.

Authors:  Jocelia P C Oliveira; Renato F Freitas; Leandro Silva de Melo; Thalita G Barros; Jorge A N Santos; Maria A Juliano; Sérgio Pinheiro; Michael Blaber; Luiz Juliano; Estela M F Muri; Luciano Puzer
Journal:  ACS Med Chem Lett       Date:  2013-12-06       Impact factor: 4.345

2.  Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer.

Authors:  Ritu Pandey; Muhan Zhou; Yuliang Chen; Dalila Darmoul; Conner C Kisiel; Valentine N Nfonsam; Natalia A Ignatenko
Journal:  Genes (Basel)       Date:  2021-05-16       Impact factor: 4.096

3.  Synthesis and Structure-Activity Relationships of N-(4-Benzamidino)-Oxazolidinones: Potent and Selective Inhibitors of Kallikrein-Related Peptidase 6.

Authors:  Elena De Vita; Niels Smits; Helma van den Hurk; Elizabeth M Beck; Joanne Hewitt; Gemma Baillie; Emily Russell; Andrew Pannifer; Véronique Hamon; Angus Morrison; Stuart P McElroy; Philip Jones; Natalia A Ignatenko; Nikolas Gunkel; Aubry K Miller
Journal:  ChemMedChem       Date:  2019-11-18       Impact factor: 3.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.